Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018067822) METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/067822 International Application No.: PCT/US2017/055348
Publication Date: 12.04.2018 International Filing Date: 05.10.2017
IPC:
A61K 39/12 (2006.01) ,A61K 39/39 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
12
Viral antigens
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
39
characterised by the immunostimulating additives, e.g. chemical adjuvants
Applicants:
PDS BIOTECHNOLOGY CORPORATION [US/US]; 675 US Highway 1 New Brunswick, NJ 08902, US
Inventors:
BEDU-ADDO, Frank; US
CONN, Greg; ES
GANDHAPUDI, Siva, K.; US
WARD, Martin; US
WOODWARD, Jerold; US
Agent:
KULKARNI, Sima, Singadia; US
Priority Data:
62/404,50405.10.2016US
Title (EN) METHODS TO ALTER THE TUMOR MICROENVIRONMENT FOR EFFECTIVE CANCER IMMUNOTHERAPY
(FR) PROCÉDÉS POUR MODIFICATION DU MICROENVIRONNEMENT TUMORAL EN VUE D'UNE IMMUNOTHÉRAPIE ANTICANCÉREUSE EFFICACE
Abstract:
(EN) Methods and compositions for altering the microenvironment of a tumor are provided. The methods comprise reducing the population of tumor-residing immune suppressive regulatory T-cells, increasing the population of tumor lysing T-cells (such as CD8+ T-cells) and improving the efficacy of cancer immunotherapy. The compositions comprise the use of cationic lipids optionally combined with autologous antigens, non-autologous antigens, or tumor-associated antigens.
(FR) L'invention concerne des procédés et des compositions visant à modifier le microenvironnement d'une tumeur. Les procédés comprennent la réduction de la population de lymphocytes T régulateurs immunosuppresseurs résidant dans une tumeur, l'augmentation de la population de lymphocytes T de lyse tumorale (par exemple des lymphocytes T CD8+) et l'amélioration de l'efficacité de l'immunothérapie anticancéreuse. Les compositions comprennent l'utilisation de lipides cationiques éventuellement combinés à des antigènes autologues, des antigènes non autologues ou des antigènes associés à une tumeur.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)